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Management of intrathoracic and cervical
anastomotic leakage after esophagectomy
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Abstract
Background: Anastomotic leakage (0–30%) after esophagectomy is a severe complication and is associated with
considerable morbidity and mortality. The aim of this study was to determine which treatment for anastomotic
leakage after esophagectomy have the best clinical outcome, based on the currently available literature.
Methods: A systematic literature search was performed in Medline, Embase, and Web of Science until April 2017.
All studies reporting on the specific treatment of cervical or intrathoracic anastomotic leakage following
esophagectomy with gastric tube reconstruction for esophageal or cardia cancer were included. The primary
outcome parameter was postoperative mortality. Methodological quality was assessed by the Newcastle-Ottawa
Quality Assessment Scale.
Results: Nineteen retrospective cohort studies including 273 patients were identified. Methodological quality of all
studies was poor to moderate. Mortality rates of intrathoracic anastomotic leakages in the treatment groups were
as follows: conservative (14%), endoscopic stent (8%), endoscopic drainage (8%), endoscopic vacuum-assisted
closure system (0%), and surgery treatment group (50%). Mortality rates of cervical anastomotic leakages in the
treatment groups were as follows: conservative (8%), endoscopic stent (29%), and endoscopic dilatation (0%).
Discussion: Due to small cohorts, heterogeneity between studies, and lack of data regarding leakage characteristics,
no evidence supporting a specific treatment for anastomotic leakage after esophagectomy was found. A severity score
based on leakage characteristics instead of treatment given is essential for determining the optimal treatment of
anastomotic leakage. In the absence of robust evidence-based treatment guidelines, we suggest customized treatment
depending on sequelae of the leak and clinical condition of the patient. PrDepartment of Surgery, Radboudumc, P.O.B.
9101/618 NLactical advices are provided.
Trial registration: Registration number PROSPERO: CRD42016032374.
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Background
The incidence of esophageal carcinoma is increasing.
Yearly, 450,000 patients are diagnosed with esophageal
cancer worldwide, and approximately 135,000 (30%) of
these patients will undergo curative resection [1, 2].
Anastomotic leakage (0–30%) is a severe complication
after esophagectomy [3, 4]. The occurrence of anasto-
motic leakage is associated with a prolonged length of
stay on the intensive care unit (ICU) and within the hos-
pital, a reduced quality of life, high costs, and an in-
creased mortality rate [4–7].
The severity of anastomotic leakage ranges from
asymptomatic to full-blown sepsis with multiple organ
failure. Factors that may influence the severity of the
anastomotic leakage are the location of the anastomosis
(intrathoracic or cervical), the size and circumference of
the defect, and the extent of contamination [8]. Factors
that influence the severity of anastomotic leakage might
also impact the most appropriate treatment strategy.
Treatment of anastomotic leakage ranges from “conser-
vative” (nil by mouth, antibiotics, gastric drainage, en-
teral or parenteral feeding, and drainage through
percutaneous tubes) to endoscopic treatment with stents
or endoscopic vacuum-assisted closure (VAC) devices,
and surgery [9]. However, no generally accepted treat-
ment strategy for the treatment of anastomotic leakage
after esophagectomy currently exists [10].
The aim of this study was to determine which treat-
ment for a cervical or intrathoracic anastomotic leakage
after esophagectomy with gastric tube reconstruction
has the best clinical outcome, based on literature
findings.
Methods
This review was registered in the PROSPERO database for
systematic reviews under number CRD42016032374 [11].
It was performed according to the Preferred Reporting
Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines, and the PRISMA checklist is shown
online in Additional file 1: Appendix 1 [12]. A systematic
literature search was performed in Medline, Embase, Web
of Science, and the Cochrane Library for studies published
from inception to April 24, 2017. The search terms used
were esophageal neoplasm or esophagectomy, and anasto-
motic leak or gastrointestinal leak, and synonyms, and
were restricted to title, abstract, and keywords (see Add-
itional file 1: Appendix 2 for the full electronic search
strategy). There were no restrictions regarding language,
year of publication, or publication status.
Study selection and data extraction
Titles, abstracts, and subsequently full-text articles were
screened independently by two authors (M.V. and S.B.),
and eligibility was assessed. All studies concerning the
treatment of cervical and/or intrathoracic anastomotic
leakage after esophagectomy for cancer of the esophagus
or gastric cardia with gastric tube reconstruction were
included. Studies not reporting the location of the anas-
tomosis were excluded. Studies primarily investigating
the treatment of other disorders affecting interruption of
esophageal integrity such as iatrogenic injuries, spontan-
eous ruptures, conduit line dehiscence, or necrosis of
the gastric conduit were excluded. In addition, review ar-
ticles, editorials, case reports or cohort studies including
fewer than five patients per specific treatment strategy,
animal studies, and studies in children were excluded.
Disagreement on eligibility was resolved after discussion.
Reference lists of all included articles were screened
manually to identify initially missed, but relevant studies.
Data was extracted by M.V. and S.B. independently and
entered into an electronic database (IBM SPSS for Win-
dows version 22.0, Armonk, NY).
Assessment of methodological quality
The risk of bias was assessed using the
Newcastle-Ottawa Quality Assessment Scale for cohort
studies [13]. This scale rates studies on 3 sources of bias
(selection, comparability, and outcome) based on 8 cri-
teria. Each criterion is awarded with 1 star except com-
parability, which is awarded a maximum of 2 stars. For
this systematic review, studies scoring 7–9 stars were
considered to be of high methodological quality, studies
scoring 4–6 stars were considered to be of moderate
methodological quality, and studies scoring 1–3 stars
were considered to be of poor methodological quality.
The methodological quality of all included studies was
assessed independently by 2 authors (M.V. and S.B.).
Disagreements were resolved by discussion and consen-
sus with a third reviewer (C.R.).
Study characteristics, leakage characteristics, and
outcome parameters
The following study characteristics were extracted: first
author, year of publication, country of origin, number of
included patients, study design (prospective or retro-
spective), type of modality used to diagnose the leakage,
type of operation, and location of the anastomosis.
Data regarding leak characterization included the fol-
lowing: time from surgery to diagnosis of the leakage,
time from diagnosis to treatment of the leakage, the
mean interval of the leakage treatment, circumference of
the leakage (0–25%, 25–50%, 50–75%, and 75–100%),
length of the leakage (in centimeters), gastric conduit
overall condition (vital, ischemic, or necrotic), and ex-
tent of the contamination (i.e., none, mediastinal fluid
collections, or pleural fluid collections).
The primary outcome parameter was mortality rate.
The secondary outcome parameters were as follows:
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success rate (when not defined by the author, defined as
alive and no persisting leakage during time of follow-up),
severe complications occurring after anastomotic leakage
treatment (Clavien-Dindo [14] ≥ 3), reintervention rate
(all surgical, endoscopic, and radiological reinterventions),
reoperation rate, new onset of (multiple) organ failure,
hospital length of stay, ICU length of stay, and quality of
life.
Analysis
Due to heterogeneity between studies, no meta-analysis
could be performed. The weighted percentages and
means were calculated to summarize the treatment out-
comes for each subgroup.
Results
Included studies
Nineteen studies, including a total of 273 patients, met
the inclusion criteria of this systematic review. A sum-
mary of the screening and selection process is shown in
Fig. 1.
Study characteristics
All 19 included studies were retrospective cohort studies
[15–33], of which 2 studies were comparative cohort
studies (Table 1) [15, 16]. An intrathoracic anastomosis
was performed in 200 patients and a cervical anasto-
mosis in 73 patients. The incidence of anastomotic leak-
age could be calculated in only 2 studies; the incidence
rates were 1% and 17%, respectively [16, 20]. The
average age of the patients was described in 6 studies;
the weighted mean was 58.0 years (range 28–92 years)
[16, 20, 21, 28, 31, 33]. Neo-adjuvant treatment was re-
ported in 1 study, in which none was given [24]. Tumor
characteristics were reported in 2 studies; in 1 study,
stage I esophageal cancer was found in 3 patients, stage
IIA in 9, stage IIB patients in 11 patients, and stage III
in 5 patients [33]. In 1 study, 8 patients were diagnosed
with adenocarcinoma and 2 patients with squamous cell
carcinoma [31]. In 3 studies, operations were performed
minimally invasively [15, 25, 30].
In 17 studies, the following modalities were used to
diagnose anastomotic leakage: contrast swallow exam-
ination (n = 15 studies), endoscopy (n = 11 studies),
and computed tomography (CT) scan (n = 10 studies).
In 6 studies, a conservative treatment was performed
consisting of the administration of antibiotics, nil by
mouth, enteral tube feeding, gastric drainage and
(percutaneous) drainage of the mediastinum, thoracic
cavity, and/or wound [18, 20, 22, 24, 29, 32]. Patients
were treated by endoscopic vacuum-assisted wound
closure (VAC) system in 1 study [17], by endoscopic
drainage in 4 studies [20, 22, 30, 33], and by endo-
scopic stent placement in 7 studies [15, 21, 23, 25–
27, 31]. In 2 studies (n = 13 patients), endoscopic bal-
loon dilatation was performed to improve the healing
of the leak [16, 18]. One study performed a
re-thoracotomy with revision of the anastomosis
(Table 2) [19]. Quality of life was not reported in any
of the studies. Severe complications were described in
Fig. 1 Summary of screening and selection process, PRISMA diagram
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15 studies [15, 16, 18, 19, 21–28, 30, 32, 33], but
none of the included studies reported the severity of
complications according to the Clavien-Dindo scale.
Methodological quality
Methodological quality of the included studies is de-
scribed in Table 3. The quality of the included studies
was poor in 9 studies [15, 18, 19, 23, 24, 26–29] and
moderate in 10 studies [16, 17, 20–22, 25, 30–33]. Ten
of the 19 studies reported on selected cases (i.e., exclud-
ing the critically ill and intensive care patients) [15, 16,
18, 26–31, 33], which is not representative of the general
hospitalized population with an anastomotic leakage
after esophageal resection.
Characteristics of anastomotic leakage
The mean time from surgery to diagnosis of the anas-
tomotic leakage was reported in 9 studies and was
9 days (range 2–30) [16, 19–22, 27–29, 33]. Only 2
studies reported the time from diagnosing the leakage
and the treatment of it (mean 8 days (range 0–20))
[16, 26]. The mean duration of the leakage treatment
was reported in 11 studies and was 34 days [16, 17,
21, 22, 24, 26–29, 31, 33]. Two studies reported the
percentage of the circumference of the leak; 1 study
Table 1 General study characteristics
Author Country Design Patients
(n)
Type of operation Outcomes reported
Intrathoracic
Griffin 2001 [18] UK NC 13 NA Mortality/success/complication/reoperation
Holscher 2003
[19]
DE NC 6 Ivor Lewis Mortality/success/complication/reoperation
Hunerbein 2004
[21]
DE NC 9 Transhiatal or Ivor
Lewis
Mortality/success/complication/reintervention/reoperation/hospital and
ICU stay
Kauer 2008 [23] DE NC 10 Ivor Lewis Mortality/success/complication/reintervention/reoperation
Tuebergen 2008
[31]
DE NC 18 Ivor Lewis Mortality/success/reintervention/reoperation/hospital stay
Qin 2010 [29] CN NC 5 Left thoracotomy Mortality/success/hospital stay
Hu 2011 [20] CN C 23 Ivor Lewis Mortality/success/reoperation/hospital stay/ICU stay
Hu 2011 [20] CN C 17 Ivor Lewis Mortality/success/reoperation/hospital stay/ICU stay
Jiang 2011 [22] CN C 7 Left thoracotomy Mortality/success/complication/hospital stay
Jiang 2011 [22] CN C 25 Left thoracotomy Mortality/success/complication/hospital stay
Yin 2012 [33] CN NC 28 Ivor Lewis Mortality/success/complication/reintervention
Al-Issa 2014 [15] DK NC 15 Ivor Lewis (some MIE) Mortality/success/complication/reintervention/hospital stay
Bludau 2014 [17] DE NC 5 Ivor Lewis Mortality/success
Shuto 2017 [30] JP NC 19 Ivor Lewis (some MIE) Mortality/success/complication/reintervention
Cervical
Orringer 1986
[28]
US NC 5 Orringer Mortality/success/complication/reintervention
Bhasin 2000 [16] IN NC 8 Orringer Mortality/success/complication/reintervention
Korst 2005 [24] US NC 13 McKeown or left
thoracotomy
Mortality/success/complication/reintervention/hospital stay
Lindeman 2008
[27]
AT NC 6 McKeown or Orringer Mortality/success/complication/reintervention
Larburu 2013
[25]
ES NC 9 McKeown or Orringer
(both MIE)
Mortality/success/complication/reoperation
Leenders 2013
[26]
NL NC 9 Orringer Mortality/success/complication/reintervention/reoperation/hospital stay
Van Rossum
2017 [32]
NL NC 23 McKeown Mortality/success/complication/reintervention/reoperation/hospital
and ICU stay
Complication = severe complication rate, hospital stay = hospital length of stay, ICU stay = ICU length of stay, Ivor Lewis = esophagectomy by laparotomy and thoracotomy
with intrathoracic anastomosis, McKeown= esophagectomy by laparotomy and thoracotomy with cervical anastomosis, MIE =minimally invasive esophagectomy, mortality
=mortality rate, Orringer = transhiatal esophagectomy with cervical anastomosis, reintervention = reintervention rate, reoperation = reoperation rate, success = success rate
C comparative, NA not available, NC non-comparative
AT Austria, CN China, DE Germany, DK Denmark, ES Spain, IN India, JP Japan, NL Netherlands, UK United Kingdom, US United States of America
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included patients with a defect less than 2/3 of the
circumference [31], the other study with a defect be-
tween 10 and 30% of the circumference [27]. The
length of the leak in centimeters was reported in 2
studies, 1 study only included patients with a leak >
1 cm [15] and 1 study only included patients with a
leak > 0.5 cm [23]. No studies reported data on the
general condition of the gastric tube. Five studies
reported data on contamination that was caused by
the leak but used different descriptions (e.g., small vs.
extended, cervical vs. intrathoracic manifestation of
the cervical leakages) [21, 22, 24, 25, 32]. In 4 pa-
tients, the leakage was associated with fistula forma-
tion to the airways (n = 2) or gastric conduit necrosis
(n = 2) [25, 31]. None of the studies reported out-
comes per anastomotic leakage characteristic, and
Table 2 Clinical study characteristics
Author Patients
(n)
Diagnosis of
leakage
General treatment Investigational
treatment
Intrathoracic
Griffin 2001 [18] 13 Contrast/endoscopy Antibiotics, nil by mouth, enteral feeding tube, gastric, mediastinal,
and thoracic drainage
Conservative
treatment
Holscher 2003
[19]
6 Contrast/endoscopy/
CT
Gastric drainage Surgery
Hunerbein 2004
[21]
9 Contrast/
endoscopy
Antibiotics, thoracic drainage Stent (plastic)
Kauer 2008 [23] 10 Contrast/
endoscopy
Mediastinal drainage Stent (SEMS)
Tuebergen 2008
[31]
18 Contrast/
endoscopy
Antibiotics, nil by mouth, enteral feeding tube, gastric, mediastinal,
and thoracic drainage
Stent (SEMS)
Qin 2010 [29] 5 Contrast Antibiotics, nil by mouth, enteral feeding tube, gastric, mediastinal,
and thoracic drainage
Conservative
treatment
Hu 2011 [20] 23 Contrast/CT Antibiotics, nil by mouth, enteral feeding tube, thoracic drainage Endoscopic drainage
Hu 2011 [20] 17 Contrast/CT Antibiotics, nil by mouth, enteral feeding tube, gastric and thoracic
drainage
Conservative
treatment
Jiang 2011 [22] 7 Contrast Nil by mouth, enteral feeding tube, gastric and thoracic drainage Conservative
treatment
Jiang 2011 [22] 25 Contrast Nil by mouth, enteral feeding tube, thoracic drainage Endoscopic drainage
Yin 2012 [33] 28 Contrast/CT Nil by mouth, enteral feeding tube, gastric drainage Endoscopic drainage
Al-Issa 2014 [15] 15 Endoscopy/CT Antibiotics, nil by mouth, enteral feeding tube, thoracic drainage Stent (SEMS)
Bludau 2014 [17] 5 Contrast/
endoscopy/CT
NA Endoscopic VAC
Shuto 2017 [30] 19 Contrast/
endoscopy/CT
Antibiotics, nil by mouth, enteral feeding tube, gastric, mediastinal,
and thoracic drainage
Endoscopic drainage
Cervical
Orringer 1986
[28]
5 NA Nil by mouth, enteral feeding tube, gastric drainage, wound
drainage
Endoscopic dilatation
Bhasin 2000 [16] 8 Contrast Nil by mouth, enteral feeding tube, wound drainage Endoscopic dilatation
Korst 2005 [24] 13 Contrast/
endoscopy/CT
Antibiotics, wound drainage Conservative
treatment
Lindeman 2008
[27]
6 NA Nil by mouth, wound drainage Stent (SEMS)
Larburu 2013
[25]
9 Contrast/
endoscopy/CT
NA Stent (SEMS)
Leenders 2013
[26]
9 NA Wound drainage or percutaneous drainage Stent (SEMS)
Van Rossum
2017 [32]
23 Contrast/
endoscopy/CT
Nil by mouth, enteral feeding tube, gastric drainage, wound
drainage
Conservative
treatment
Conservative treatment = antibiotics/nil by mouth/enteral feeding tube/gastric drainage/mediastinal drainage/thoracic drainage/percutaneous drainage/wound
drainage; contrast = contrast swallow examination
CT computerized tomography, NA not available, SEMS self-expandable metallic stent
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therefore, no further analysis of the effectiveness of
different treatment modalities per leakage characteris-
tic could be performed.
Outcomes of anastomotic leakage treatment
All studies
The overall mortality was 11% (31/273 patients). The
mortality rates were as follows: 12% (9/78 patients) in
the conservative group, 14% (11/76 patients) in the
endoscopic stent group, 8% (8/95 patients) in the endo-
scopic drainage group, 0% (0/5 patients) in the endo-
scopic VAC therapy, 0% (0/13 patients) in the
endoscopic dilatation group, and 50% (3/6 patients) in
the surgical treatment group (Table 4). Only two studies
reported the new onset of (multiple) organ failure,
respectively 14% (1/7 patients) and 50% (3/6 patients) of
patients [19, 22]. Other outcome parameters are re-
ported in Table 5.
Subgroup—intrathoracic anastomotic leakage
The overall mortality after intrathoracic anastomotic
leakage was 11% (21/200 patients). The mortality rates
were as follows: 14% (6/42 patients) in the conservative
group, 8% (4/52 patients) in the endoscopic stent group,
8% (8/95 patients) in the endoscopic drainage group, 0%
(0/5 patients) in the endoscopic VAC therapy group, and
50% (3/6 patients) in the surgical treatment group
(Table 4). The reintervention rate was higher in the
endoscopic stent group compared to other treatment
groups: 19 patients (37%) needed at least 1 reinterven-
tion, most often because of stent migration. Table 6 pro-
vides an overview of the other outcome measures.
Subgroup—cervical anastomotic leakage
The overall mortality after cervical anastomotic leakage
was 14% (10/73 patients). The mortality rates were as
follows: 8% (3/36 patients) in the conservative treatment
group, 29% (7/24 patients) in the endoscopic stent
group, and 0% (0/13 patients) in the endoscopic dilata-
tion group (Table 4). The reintervention and reoperation
rates were 53% (8/15 patients) and 44% (4/9 patients) in
the endoscopic stent group. Table 7 provides an over-
view of the other outcome measures.
Discussion
This is the first systematic review summarizing the re-
sults of different treatment strategies for anastomotic
leakage in patients after esophagectomy with gastric tube
reconstruction.
Results on conservative, endoscopic, and surgical
treatment were reported in 6 studies, 14 studies, and 1
study, respectively. The mean overall mortality rate was
11%. In studies reporting the outcome of conservative
treatment, the mean mortality was 12%, in the stent
placement group 14%, and in the endoscopic drainage
group 8%. For endoscopic VAC, endoscopic dilatation,
and surgical treatment, the mortality rate could not reli-
ably be estimated due to a low number of patients
reported.
Strengths and limitations
Furthermore, this review reports factors that (may) influ-
ence the severity and outcome of an anastomotic leak-
age. A potential limitation of this review is that many
studies were excluded based on title and abstract due to
not reporting treatment results for cervical and intratho-
racic leakage separately. Aware of the fact that more
data on anastomotic leakage is available, we did not in-
clude these studies because it would not contribute in
finding an answer to our research question. In addition,
the methodological quality of the included studies was
limited. Half of the studies reported results of a highly
selected group of patients, which makes the external val-
idity of these data weak. All studies were retrospective
and included a limited number of patients. The objective
of the present study was to investigate the treatment of
anastomotic leakages; however, due to a lack of reported
baseline characteristics and definitions of anastomotic
Table 4 Primary outcome: mortality rate
Studies, n Included patients, n Mortality, n (%)
Overall
Conservative 6 78 9 (12%)
Endoscopic
Stent 7 76 11 (14%)
Drainage 4 95 8 (8%)
Endoscopic VAC 1 5 0 (0%)
Dilatation 2 13 0 (0%)
Surgical 1 6 3 (50%)
Intrathoracic anastomotic leakage
Conservative 4 42 6 (14%)
Endoscopic
Stent 4 52 4 (8%)
Drainage 4 95 8 (8%)
Endoscopic VAC 1 5 0 (0%)
Surgical 1 6 3 (50%)
Cervical anastomotic leakage
Conservative 2 36 3 (8%)
Endoscopic
Stent 3 24 7 (29%)
Dilatation 2 13 0 (0%)
VAC vacuum-assisted closure
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leakages, it remains unclear whether these cohorts and
leakage rates are comparable. Furthermore, additional
treatments (e.g., nil by mouth, nutritional support, gas-
tric drainage) which patients received alongside the in-
vestigational treatment were different between studies or
not specified. Characterization of the leak and defini-
tions of outcome parameters used were frequently lack-
ing and not comparable between studies. Because of the
heterogeneity of the included studies, performing a
meta-analysis was deemed not scientifically and clinically
relevant. Finally, multiple forms of bias were found in
the data, i.e., in 13 studies, the follow-up length was not
reported or too short to find long-term complications,
i.e., stricture and fistula formation, or stent migration
and 10 studies reported on selected cases (i.e., excluding
the critically ill and intensive care patients).
Clinical implications
Based on the currently available evidence, it is not possible
to provide a uniform strategy for the treatment of anasto-
motic leakage after esophagectomy. Although achieving
the aim of this systematic review was not entirely possible
with the currently available evidence, this review is highly
instrumental in exposing the limitations of the current
evidence and therefore uncovering areas for future re-
search. Firstly, it is important to separately report out-
comes of intrathoracic and cervical anastomotic leaks,
Table 5 Other outcome parameters
Studies, n Included patients, n Outcome, n (%)
Mortality rate
Conservative 6 78 9 (12%)
Endoscopic
Stent 7 76 11 (14%)
Drainage 4 95 8 (8%)
Endoscopic VAC 1 5 0 (0%)
Dilatation 2 13 0 (0%)
Surgical 1 6 3 (50%)
Success rate
Conservative 6 78 69 (88%)
Endoscopic
Stent 7 76 57 (75%)
Drainage 4 95 86 (91%)
Endoscopic VAC 1 5 5 (100%)
Dilatation 2 13 13 (100%)
Surgical 1 6 3 (50%)
Severe complications
Conservative 4 56 9 (16%)
Endoscopic
Stent 6 58 27 (47%)
Drainage 3 72 13 (18%)
Endoscopic VAC NA NA
Dilatation 2 13 5 (38%)
Surgical 1 6 3 (50%)
Reinterventions
Conservative 2 36 5 (36%)
Endoscopic
Stent 6 67 27 (40%)
Drainage 2 47 10 (21%)
Endoscopic VAC NA NA NA
Dilatation 2 13 5 (38%)
Surgical NA NA NA
Mean number of reinterventions
Conservative 2 36 3
Endoscopic
Stent 6 67 1
Drainage 2 47 1
Endoscopic VAC NA NA NA
Dilatation 2 13 4
Surgical NA NA NA
Reoperations
Conservative 3 53 2 (4%)
Endoscopic
Stent 4 46 6 (13%)
Table 5 Other outcome parameters (Continued)
Studies, n Included patients, n Outcome, n (%)
Drainage 1 23 1 (4%)
Endoscopic VAC NA NA NA
Dilatation NA NA NA
Surgical 1 6 2 (33%)
Hospital length of stay
Conservative 4 65 41 days
Endoscopic
Stent 4 51 37 days
Drainage 2 48 42 days
Endoscopic VAC NA NA NA
Dilatation NA NA NA
Surgical NA NA NA
ICU length of stay
Conservative 2 40 16 days
Endoscopic
Stent 1 9 25 days
Drainage 1 23 12 days
Endoscopic VAC NA NA NA
Dilatation NA NA NA
Surgical NA NA NA
VAC vacuum-assisted closure, NA not available
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because evidence suggests that these are separate
entities and probably necessitate different treatment
strategies [4, 34]. Secondly, a uniform definition of
anastomotic leakage, including factors that may influ-
ence the severity of anastomotic leakages and outcome
parameters, should be described to make data transpar-
ent and comparable between studies. These factors may
include length of the leak, circumference of the leak,
condition of the gastric tube (vital, ischemic, necrotic),
and contamination caused by the leak [35]. Adequate
description of anastomotic leakage makes it possible to
evaluate whether these factors actually contribute to
leak severity and compare different treatment strat-
egies. This may lead to an anastomotic leakage severity
score. A score based on leakage characteristics, rather
than a scoring system based on leakage therapy (e.g.,
the ECCG grading system [36]), is essential for provid-
ing clinicians an optimal treatment strategy for patients
with an anastomotic leak. No evidence-based recom-
mendations could be provided from the literature. For
the current practice, we recommend, based on our ex-
periences, all patients with an anastomotic leakage
should be treated with intravenous antibiotics, nasogas-
tric tube drainage, and where possible enteral feeding
through a jejunal feeding tube or jejunostomy. In case
of a cervical anastomosis, the neck wound should be
opened. Additional interventions depend on the seque-
lae of the leak and the condition of the patient. Un-
drained collections of the mediastinum and thoracic
cavity should be drained by surgical or radiological
placed percutaneous drains and/or an endoscopic suc-
tion tube through the anastomotic defect. If drainage is
insufficient or in case of more extensive contamination,
a more aggressive strategy may be appropriate and
drainage can be performed by video-assisted thoraco-
scopic surgery (VATS) or thoracotomy. In addition to
Table 6 Outcomes intrathoracic anastomosis
Studies (n) Included patients (n) Outcome
Mortality rate
Conservative 4 42 6 (14%)
Endoscopic
Stent 4 52 4 (8%)
Drainage 4 95 8 (8%)
Endoscopic VAC 1 5 0 (0%)
Surgical 1 6 3 (50%)
Success rate
Conservative 4 42 36 (86%)
Endoscopic
Stent 4 52 40 (77%)
Drainage 4 95 86 (91%)
Endoscopic VAC 1 5 5 (100%)
Surgical 1 6 3 (50%)
Severe complications
Conservative 2 20 3 (15%)
Endoscopic
Stent 3 34 14 (41%)
Drainage 3 72 13 (18%)
Endoscopic VAC NA NA NA
Surgical 1 6 3 (50%)
Reinterventions
Conservative NA NA NA
Endoscopic
Stent 4 52 19 (37%)
Drainage 2 47 10 (21%)
Endoscopic VAC NA NA NA
Surgical NA NA NA
Mean number of reinterventions
Conservative NA NA NA
Endoscopic
Stent 4 52 1
Drainage 2 47 1
Endoscopic VAC NA NA NA
Surgical NA NA NA
Reoperations
Conservative 2 30 1 (33%)
Endoscopic
Stent 3 37 2 (5%)
Drainage 1 23 1 (4%)
Endoscopic VAC NA NA NA
Surgical NA NA 2 (33%)
Hospital length of stay
Conservative 3 29 64 days
Table 6 Outcomes intrathoracic anastomosis (Continued)
Studies (n) Included patients (n) Outcome
Endoscopic
Stent 3 42 38 days
Drainage 2 48 42 days
Endoscopic VAC NA NA NA
Surgical NA
ICU length of stay
Conservative 1 17 34 days
Endoscopic
Stent 1 9 25 days
Drainage 1 23 12 days
Endoscopic VAC NA NA NA
Surgical NA NA NA
NA not available
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drainage of fluid collections, the defect can be closed
surgically or covered/closed with an endoscopically
placed stent or E-VAC system. However, more data is
needed to evaluate the effectiveness of these recom-
mendations. In this review, we showed that there are
multiple treatments and strategies to treat anastomotic
leakage. Together with the incidence of anastomotic
leakage, it is unlikely that single-center cohort studies
will include enough patients to provide robust data for
an anastomotic leakage treatment strategy. More
detailed data from a larger cohort is urgently needed to
provide an evidence-based treatment strategy for anas-
tomotic leakage after esophagectomy. Currently, the
TENTACLE study (TreatmENT of AnastomotiC Leak-
age after Esophagectomy), an international retrospect-
ive cohort study on patients with an anastomotic
leakage after esophagectomy for esophageal cancer, is
being performed (NCT03829098) [37]. This study in-
cludes standardized characteristics of an anastomotic
leakage and has a standardized outcome. This study
could provide answers to current issues as which fac-
tors determine the severity of the leakage and which
treatment options have the best outcomes.
Conclusions
Due to small cohorts in the included studies, heterogen-
eity between studies and lack of data regarding leakage
characteristics, no evidence supporting a specific treat-
ment for anastomotic leakage after esophagectomy was
found. A severity score based on leakage characteristics
instead of treatment given is needed for determining the
optimal treatment of anastomotic leakage. In the ab-
sence of robust evidence-based treatment guidelines, we
recommend an individualized treatment depending on
sequelae of the leak and condition of the patient.
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